CD8A and cancer: The recent data demonstrating that vaccines constituted by mutation-derived CD4+/CD8+ T cell neoepitopes induce anti-tumor immune responses in both preclinical and clinical settings (20, 21), had prompted us to test whether the unique properties of OMVs could be exploited in cancer immunotherapy.